Enasidenib - Wikipedia
WEBEnasidenib, sold under the brand name Idhifa, is an anti-cancer medication used to treat relapsed or refractory acute myeloid leukemia. [2][3] It is an inhibitor of isocitrate dehydrogenase 2 (IDH2). [2]
FDA approves new targeted treatment for relapsed or refractory …
WEBThe U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific...
IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia
WEBWHAT IS IDHIFA ® (enasidenib)? IDHIFA ® is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s).
Enasidenib (Oral Route) Description and Brand Names - Mayo Clinic
WEBEnasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment. Enasidenib is an isocitrate dehydrogenase-2 inhibitor.
Enasidenib Uses, Side Effects & Warnings - Drugs.com
WEBMay 24, 2024 · What is enasidenib? Enasidenib is used to treat acute myeloid leukemia (AML) in adults with an IDH2 mutation. enasidenib is used when AML has come back or has not improved with prior treatment. Enasidenib may also be used for purposes not listed in this medication guide.
Enasidenib in acute myeloid leukemia: clinical development and ...
WEBAug 30, 2019 · Enasidenib is a promising FDA approved agent in the treatment of R/R AML. Through preclinical and clinical evaluation, enasidenib has demonstrated remarkable activity in patients with mutated IDH2. Although generally well tolerated, enasidenib does require careful monitoring throughout its treatment course.
FDA Approves Enasidenib (Idhifa), a First-of-Its-Kind Drug, for ...
WEBAug 2, 2017 · Enasidenib is approved for people with relapsed or refractory AML that tests positive for an IDH2 mutation, as determined by an FDA-approved test.
Enasidenib Mesylate - NCI - National Cancer Institute
WEBEnasidenib mesylate is approved to treat: Acute myeloid leukemia (AML) that has recurred (come back) or is refractory (does not respond to treatment). It is used in adult patients whose AML has a mutation in the IDH2 gene .
FDA granted regular approval to enasidenib for the treatment of ...
WEBOn August 1, 2017, the U.S. Food and Drug Administration granted regular approval to enasidenib (IDHIFA, Celgene Corp.) for the treatment of adult patients with relapsed or refractory acute...
Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute …
WEBMay 1, 2018 · Enasidenib is a novel, oral, small-molecule inhibitor of the IDH2 enzyme. Specifically, it targets mutant IDH2 variants R140Q, R172S, and R172K, leading to decreased serum 2-HG levels and therefore an increased rate of myeloid differentiation and reduced blast counts (Celgene Corporation, 2017). Figure 1.